



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on <u>4-23-2004</u>	
Terresa Alexander Name Signature	<u>Terresa Alexander</u>
Signature	

P&G Case 9118M2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :  
Douglas Craig Scott, et al : Confirmation No. 5133  
Serial No. 10/706,103 : Group Art Unit 1642  
Filed November 12, 2003 : Examiner

For Chewable Solid Unit Dosage Forms and Methods for Delivery of Active Agents into  
Occlusal Surfaces of Teeth

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1.  **37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)**

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2.  37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3.  37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4.  37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5.  Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case). This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

**ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:**

**[X]** (1) (For use with applications filed prior to or on June 30, 2003.) Copies of the cited documents are enclosed.

OR

**[ ]** (2) (For use with applications filed after June 30, 2003.) In accordance with 37 C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non-patent literature.

OR

**[ ]** (3) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. \_\_\_\_, U.S. Patent Application Serial No. \_\_\_, filed \_\_\_. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR

**[ ]** (4) Copies of all said documents, except Cite Numbers \_\_\_\_\_, were submitted and considered in parent application U.S. Patent Application Serial No. \_\_\_\_\_, filed \_\_\_\_\_. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

**[X]** (5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided. WO 97/19668 the invention relates to a toothpaste and mouthwash in tablets which dissolve in the mouth when contacting saliva and provide for the cleaning and rinsing of the mouth, practically anywhere and without the use of a toothbrush and water. The object of the invention is to provide people with an easy dental cleaning due to a novel presentation of the toothpaste and mouthwash, in order to contribute to the prevention of periodontal diseases; each tablet comprises ascorbic acid 18 mg, sodium bicarbonate 50 mg, tricalcic phosphate 40 mg, sodium laurilsulfate 17 mg, Arabic gum 70 mg and natural sweetness and flavouring agents 150 mg.

**[X]** (6) Applicants also respectfully request the Examiner to consider and make of record the co-pending applications listed on the attached page.

Additional information is attached.

Respectfully submitted,

By Betty J. Zea  
Betty J. Zea  
Attorney for Applicants  
Registration No. 36,069  
(513) 622-3952

Date: April 23 2004  
**Customer No. 27752**

**CO-PENDING U.S. APPLICATIONS**Atty. Docket No.

9118M

Serial Number

10/706,104

Inventor(s)

Scott, et al

Filing Date

November 12, 2003

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

COMPLETE IF KNOWN

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 2

Application Number	10/706,103
Confirmation Number	5133
Filing Date	November 12, 2003
First Named Inventor	Douglas Craig Scott
Group Art Unit	1642
Examiner Name	
Attorney Docket Number	9118M2

### U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	US-1,110,900	09-15-1914	James Henry Core	
	2	US-3,342,687	09-19-1967	David Huntington Gould	
	3	US-3,431,339	07-20-1966	KW Gyarmathy, et al	
	4	US-3,450,812	06-17-1969	Don Navarro Harris	
	5	US-3,497,590	02-24-1970	Edward Eigen	
	6	US-3,518,343	06-30-1970	Welsh, et al	
	7	US-3,531,564	09-29-1970	Bouchal, et al	
	8	US-3,577,490	05-04-1971	Welsh, et al	
	9	US-3,888,976	06-10-1975	Mikvy, et al	
	10	US-3,962,417	06-08-1976	Howell	
	11	US-4,132,772	01-02-1979	Barth et al	
	12	US-4,308,252	12-29-1981	Tomaich et al	
	13	US-4,569,852	02-11-1986	Yang	
	14	US-4,753,792	06-28-1988	Aberg	
	15	US-5,057,305	10-15-1991	Aberg	
	16	US-5,153,005	10-06-1992	Groberg	
	17	US-5,284,659	02-08-1994	Cherukuri et al	
	18	US-5,302,375	04-12-1994	Viscio	
	19	US-5,476,647	12-19-1995	Chow et al	
	20	US-5,496,541	03-05-1996	Cutler	
	21	US-5,670,138	09-23-1997	Vanema, et al	
	22	US-5,891,448	04-06-1999	Chow, et al	
	23	US-5,965,110	12-12-1999	Arnold	
	24	US-6,086,854	07-11-2000	Arnold	
	25	US-6,177,097	01-23-2001	Hanke	
	26	US-2002/0068038	06-06-2002	Yang	

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT			Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
	27	CA	850070		Colgate Palmolive Co.		
	28	FR	1515046		Colgate Palmolive Co.		
	29	GB	1142377		Colgate Palmolive Co.		
	30	GB	1110900		Colgate Palmolive Co.		
	31	GB	1081106		Colgate Palmolive Co.		
	32	WO	97/19668		Solicitante		
	33	WO	99/33437		The Procter & Gamble Co.		
	34	WO	88/10110		Dentab, Inc.		

EXAMINER

DATE CONSIDERED

Please type a plus sign (+) inside this box → [+]

PTO/SB/08B (08-03)

**U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE**

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

<p style="text-align: center;">Substitute for form 1449A/PTO</p> <p style="text-align: center;"><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p style="text-align: center;">(use as many sheets as necessary)</p> <p style="text-align: center;">SHEET 2 of 2</p>	<p style="text-align: center;"><b>COMPLETE IF KNOWN</b></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td style="width: 50%;">10/706,103</td> </tr> <tr> <td>Confirmation Number</td> <td>5133</td> </tr> <tr> <td>Filing Date</td> <td>November 12, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Douglas Craig Scott</td> </tr> <tr> <td>Group Art Unit</td> <td>1642</td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td>9118M2</td> </tr> </table> <div style="text-align: right; margin-top: -20px;"> </div>	Application Number	10/706,103	Confirmation Number	5133	Filing Date	November 12, 2003	First Named Inventor	Douglas Craig Scott	Group Art Unit	1642	Examiner Name		Attorney Docket Number	9118M2
Application Number	10/706,103														
Confirmation Number	5133														
Filing Date	November 12, 2003														
First Named Inventor	Douglas Craig Scott														
Group Art Unit	1642														
Examiner Name															
Attorney Docket Number	9118M2														

## **NON PATENT LITERATURE DOCUMENTS**

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	35	HASSELL, T.M./GABATHULER, H./MUHLEMANN, H.R., "A Ratio Telemetric Study of Oral Fluoride Clearance", <i>Helv. Odont. Acta</i> , April 1971, pg 29-35	
	36	HENNON, DAVID K., D.D.S., "Brief Clinical and Laboratory Observations", <i>Journal of Pediatrics</i> , June 1972 Vol. 80, No. 6, pp 1018-1021	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.